Your browser doesn't support javascript.
loading
Reduced alpha diversity of the oral microbiome correlates with short progression-free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib-based therapy (AGMT MM 1, phase II trial).
Ludwig, Heinz; Hausmann, Bela; Schreder, Martin; Pönisch, Wolfram; Zojer, Niklas; Knop, Stefan; Gunsilius, Eberhard; Egle, Alexander; Petzer, Andreas; Einsele, Hermann; Hajek, Roman; Weisel, Katja; Krenosz, Karl Jochen; Lang, Alois; Lechner, Daniel; Greil, Richard; Berry, David.
Afiliación
  • Ludwig H; Wilhelminen Cancer Research Institute Vienna Austria.
  • Hausmann B; Joint Microbiome Facility (JMF) Medical University of Vienna & University of Vienna Vienna Austria.
  • Schreder M; Department of Laboratory Medicine Medical University of Vienna Vienna Austria.
  • Pönisch W; Division of Hematology and Medical Oncology Department of Internal Medicine II Würzburg University Medical Center Würzburg Germany.
  • Zojer N; Department of Hematology University of Leipzig Leipzig Germany.
  • Knop S; Department of Medicine I Wilhelminenspital Vienna Austria.
  • Gunsilius E; Division of Hematology and Medical Oncology Department of Internal Medicine II Würzburg University Medical Center Würzburg Germany.
  • Egle A; Department of Internal Medicine V Medical University Innsbruck Innsbruck Austria.
  • Petzer A; Department of Internal Medicine III with Haematology Medical Oncology, Hemostaseology Infectiology and Rheumatology Oncologic Center Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR) Paracelsus Medical University Cancer Cluster Salzburg Salz
  • Einsele H; Department of Internal Medicine I Ordensklinikum Linz BHS-EKH, Linz Linz Austria.
  • Hajek R; Division of Hematology and Medical Oncology Department of Internal Medicine II Würzburg University Medical Center Würzburg Germany.
  • Weisel K; Department of Hematooncology University Hospital Ostrava Ostrava Czech Republic.
  • Krenosz KJ; University of Tübingen Tübingen Germany.
  • Lang A; Department of Internal Medicine 3 Kepler Universitätsklinikum GmbH Med Campus III Linz Austria.
  • Lechner D; Innere Medizin II LKH Feldkirch Feldkirch Austria.
  • Greil R; Department of Medicine I - Hematology with Stem Cell Transplantation Hemostaseology and Medical Oncology Ordensklinikum Linz Elisabethinen Linz Austria.
  • Berry D; Department of Internal Medicine III with Haematology Medical Oncology, Hemostaseology Infectiology and Rheumatology Oncologic Center Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR) Paracelsus Medical University Cancer Cluster Salzburg Salz
EJHaem ; 2(1): 99-103, 2021 Feb.
Article en En | MEDLINE | ID: mdl-35846090
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: EJHaem Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: EJHaem Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos